More than 30 million Americans suffer from unrelieved chronic pain, such as nerve injury-induced neuropathic pain. Although a considerable amount is known about how chronic pain is induced, little is known about how acute pain naturally resolves. We hypothesize that disruption of local active pro-resolving processing will result in chronic pain. Current management of chronic pain mainly focuses on two types of drugs, ones that treat pain symptoms by blocking neurotransmission and those that modify disease progression by suppressing neuroinflammation. We now propose a novel approach for chronic pain therapy, using newly uncovered endogenous pro-resolving mediators. This approach focuses on novel endogenous lipid mediators namely resolvins and protectins that bring damaged system back to homeostasis by enhancing the phagocytic activity and clearance of local macrophages. Our recent results show that resolvins and protectins are very potent pro-resolving and anti-inflammatory agonists. Work in progress demonstrates that these novel endogenous mediators are also very effective, in nanogram dose range, in producing anti- hyperalgesic effects in animal models of inflammatory pain and neuropathic pain. We hypothesize that diminished production of resolvins and protectins after nerve injury will lead to the development of chronic pain. The overall goal of this application is to investigate whether and how resolvins and protectins can prevent and reverse neuropathic pain after nerve injury. We will employ multidisciplinary approaches, such as newly developed lipid mediator-lipidomics-informatics, animal behavior, electrophysiology, and several new biochemical systems including in vivo and in vitro assessment of macrophage phagocytosis to define the anti- hyperalgesic, pro-resolving, and anti-inflammatory roles of resolvins and protectins in animal models of neuropathic pain. These studies will involve formation of innovative partnership between Dr. Ji's pain research laboratory and Dr. Serhan's inflammation research group in the same department. In view of the results from work in progress, the results from the proposed studies will be transformative and have considerable impact on the entire pain community, from acute postoperative pain to chronic inflammatory pain and neuropathic pain.

Public Health Relevance

Although a considerable amount is known about how chronic pain is induced, little is known about how acute pain naturally resolves. We propose a novel approach for chronic pain therapy, using newly uncovered endogenous pro-resolving lipid mediators, namely resolvins and protectins. We will employ multidisciplinary approaches to define the anti-hyperalgesic, pro-resolving, and anti-inflammatory roles of resolvins and protectins in animal models of neuropathic pain. The results from the proposed studies will be transformative and have considerable impact on the entire pain community, from acute postoperative pain to chronic inflammatory and neuropathic pain.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
7R01NS067686-04
Application #
8509936
Study Section
Special Emphasis Panel (ZRG1-BCMB-A (51))
Program Officer
Porter, Linda L
Project Start
2009-09-15
Project End
2014-08-31
Budget Start
2012-04-01
Budget End
2012-08-31
Support Year
4
Fiscal Year
2011
Total Cost
$51,520
Indirect Cost
Name
Duke University
Department
Anesthesiology
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Martini, Alessandra Cadete; Berta, Temugin; Forner, Stefânia et al. (2016) Lipoxin A4 inhibits microglial activation and reduces neuroinflammation and neuropathic pain after spinal cord hemisection. J Neuroinflammation 13:75
Liu, Chien-Cheng; Gao, Yong-Jing; Luo, Hao et al. (2016) Interferon alpha inhibits spinal cord synaptic and nociceptive transmission via neuronal-glial interactions. Sci Rep 6:34356
Berta, T; Qadri, Y J; Chen, G et al. (2016) Microglial Signaling in Chronic Pain with a Special Focus on Caspase 6, p38 MAP Kinase, and Sex Dependence. J Dent Res 95:1124-31
Sisignano, Marco; Angioni, Carlo; Park, Chul-Kyu et al. (2016) Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain. Proc Natl Acad Sci U S A 113:12544-12549
Chen, Gang; Xie, Rou-Gang; Gao, Yong-Jing et al. (2016) ?-arrestin-2 regulates NMDA receptor function in spinal lamina II neurons and duration of persistent pain. Nat Commun 7:12531
Xu, Zhen-Zhong; Kim, Yong Ho; Bang, Sangsu et al. (2015) Inhibition of mechanical allodynia in neuropathic pain by TLR5-mediated A-fiber blockade. Nat Med 21:1326-31
Chen, Gang; Park, Chul-Kyu; Xie, Rou-Gang et al. (2015) Intrathecal bone marrow stromal cells inhibit neuropathic pain via TGF-? secretion. J Clin Invest 125:3226-40
Mirakaj, Valbona; Dalli, Jesmond; Granja, Tiago et al. (2014) Vagus nerve controls resolution and pro-resolving mediators of inflammation. J Exp Med 211:1037-48
Colas, Romain A; Shinohara, Masakazu; Dalli, Jesmond et al. (2014) Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am J Physiol Cell Physiol 307:C39-54
Ji, Ru-Rong; Xu, Zhen-Zhong; Gao, Yong-Jing (2014) Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov 13:533-48

Showing the most recent 10 out of 51 publications